Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: JACC Heart Fail. 2020 Aug 12;8(10):834–843. doi: 10.1016/j.jchf.2020.06.008

Central Illustration. Effect of sacubitril/valsartan on clinical outcomes by 8 weeks post-randomization according to the dose of blinded study drug achieved at week 4.

Central Illustration.

KaplanMeier estimates of the clinical composite of cardiovascular death or rehospitalization for heart failure are shown. Treatment with sacubitril/valsartan, as compared with enalapril, significantly reduced the risk of cardiovascular death or rehospitalization for heart failure in patients who achieved the target dose of study drug and in those who did not.